Eli Lilly – Talk Bio

Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

3 days ago talkbio0Tagged Abnormal, aspects of adverse effects, Dysesthesia, Eli, Eli Lilly, Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Obesity, Phase III, retatrutide, safety signal, sense of, Therapeutic tactile stimulation, triple agonist, triple hormone receptor agonist, TRIUMPH-4, Weight Loss

Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

3 weeks ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

Lilly Prepares Amylin-Based Obesity Drug Eloralintide for Phase III After Strong Weight Loss Results

1 month ago talkbio0Tagged Agonist, Amylin, Clinical Development, Eli, Eli Lilly, Eloralintide, Obesity Drug, Phase 3 Clinical Trials, Weight Loss

Eli Lilly; eloralintide; amylin agonist; obesity drug; Phase III trial; weight loss; clinical development

Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices

1 month ago talkbio0Tagged drug price, Eli Lilly, Glucagon-Like Peptide 1, Medicare coverage, Novo Nordisk, Obesity, Trump administration, Wegovy, White House, Zepbound

Lilly; Novo Nordisk; White House; obesity drug prices; Medicare coverage; GLP-1 medications; Trump administration; Zepbound; Wegovy

Lilly’s Oral GLP-1, Orforglipron, Achieves Two New Clinical Wins in Type 2 Diabetes

2 months ago talkbio0Tagged ACHIEVE-1, ATTAIN-2, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Effectiveness, Eli Lilly, Farxiga, Glucagon-Like Peptide 1, Oral cavity, orforglipron, regulatory submission, Safety, semaglutide, Weight Loss

Lilly; Orforglipron; oral GLP-1; type 2 diabetes; clinical trial; weight loss; regulatory submission; ACHIEVE-1; ATTAIN-2; semaglutide; Farxiga; efficacy; safety

Eli Lilly’s Oral SERD Inluriyo Approved by FDA for ESR1-Mutated Breast Cancer

3 months ago talkbio0Tagged Approved, Carcinoma breast stage IV, Eli, Eli Lilly, EMBER-3 trial, ESR1 gene, Estrogen receptor positive, HER2-negative, Imlunestrant, Inluriyo, Mutation, Oral SERD, United States Food and Drug Administration

Eli Lilly; Inluriyo; oral SERD; imlunestrant; FDA approval; ESR1 mutation; metastatic breast cancer; estrogen receptor positive; HER2-negative; EMBER-3 trial

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

3 months ago talkbio0Tagged bimagrumab, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Obesity, regulatory strategy, tirzepatide, Trial Termination, Zepbound

Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

3 months ago talkbio0Tagged alpha 1-antitrypsin, cardiometabolic, Eli, Eli Lilly, Generation Park, Houston, Immunology, Investments, Manufacturing, Neoplasms, Neuroscience discipline, pharmaceutical manufacturing, small molecule medicines

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience